2. Preclinical MASH trial Submitted and accepted by FDA...SP goes UP a little more!!
Pre-clinical would be an animal study and would not have to be submitted to the the FDA. They should have started that immediately after receiving the approval on shares. With the current climate at Cytodyn they may not announce that until the results are in.
3. MASH Phase 2B trial submitted and accepted SP goes up!!!
The previous trial that was done looked at dosing and efficacy, a phase 2a/2b trial. The positive results mean we should be able to go directly to a phase 3 trial.
4. MERCK KEYTRUDA/LL results in CRC ...SP goes up
The results almost certainly showed that leronlimab alone was as effective as a leronlimab/checkpoint inhibitor combo without the nasty side effects of the checkpoint inhibitor. Whomever the company was that sponsored that study will never release those findings.
The rest is highly speculative.